LVAD Panel Review Raises Profile Of Medicare Cost Effectiveness Evaluation
This article was originally published in The Gray Sheet
Executive Summary
The cost-effectiveness of new therapies should be considered by CMS during the Medicare coverage process, according to some members of the Medicare Coverage Advisory Committee
You may also be interested in...
Medicare deadline for LVADs
July 14 due date is set for the Medicare Coverage Advisory Committee's final decision on coverage of left ventricular assist devices as destination therapy (1"The Gray Sheet" March 17, 2003, p. 16). 2Minutes and a transcript for the March 12 MCAC meeting are now available...
Medicare deadline for LVADs
July 14 due date is set for the Medicare Coverage Advisory Committee's final decision on coverage of left ventricular assist devices as destination therapy (1"The Gray Sheet" March 17, 2003, p. 16). 2Minutes and a transcript for the March 12 MCAC meeting are now available...
AdvaMed Medicare Policy Meeting In Brief
New tech add-on application status: Medtronic InFuse bone graft/LT-Cage lumbar tapered fusion system's acceptance for add-on payment under the hospital inpatient prospective payment system will depend on the content of "data [gathered] between the proposed rule and final, to assess whether it meets the payment adequacy test," Stephen Philips, CMS division of acute care deputy director, reported at the AdvaMed seminar on Medicare policy in Baltimore May 8. The firm was denied a new tech add-on payment last year due to insufficient data (1"The Gray Sheet" July 6, 2002, p. 9). The inpatient proposed rule is slated for May 21 release....Guilford Gliadel wafer: New tech add-on payment likely will be denied for use in patients undergoing surgery for newly diagnosed malignant glioma, an indication approved in February, because the product was originally approved in 1996. Therefore, receiving a new ICD-9 code "does not start the clock ticking anew as far as [being classified as a] new technology," CMS' Philips explained May 8...